Q-omics provides the consensus-scored C3orf35 profile across patient tissues and cancer cell-line models. C3orf35 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, C3orf35 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, C3orf35 RNA expression shows 17,514 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, and UVM as cancer lineages where C3orf35 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C3orf35 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C3orf35 survival associations across molecular data types. C3orf35 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C3orf35 RNA expression–survival associations across cancer types. High C3orf35 expression shows unfavorable associations in KIRC, ACC, LIHC, KICH and STAD, but favorable associations in SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for C3orf35 RNA expression.
This table summarizes C3orf35 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for C3orf35. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C3orf35 shows higher tumor expression in KIRC, COAD, LIHC, BLCA, CHOL and READ. The KIRC box plot shows higher C3orf35 RNA expression in tumor versus normal tissue (log2 FC = +0.092, t-test p < 0.001).
This table shows molecular features associated with C3orf35 in patient tissues and cancer cell lines. In patient samples, C3orf35 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, C3orf35 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE.
